Differential Antigen Processing by Dendritic Cell Subsets in Vivo Authors: Dudziak et al., published in Science, 2007

Background and Scientific Context

Dendritic cells (DCs) are key players in the immune system. They process and present antigens (foreign or self molecules) to T cells, which helps initiate immune responses or maintain tolerance. DCs come in different subtypes, each potentially having distinct roles.

This study focuses on two main subtypes of dendritic cells found in mouse spleen:

  • CD8⁺DEC205⁺ DCs – Known for cross-presentation of antigens via MHC class I (important for activating CD8⁺ cytotoxic T cells).

  • CD8⁻33D1⁺ DCs – Less is known, suspected to be more specialized in MHC class II presentation (important for activating CD4⁺ helper T cells).

Key Question:
Do these two DC subsets process and present antigens differently in vivo? If yes, how is this regulated at the molecular level?

Experimental Design and Methods

To investigate antigen processing:

  • The researchers used antibody-antigen fusion constructs to target antigens specifically to either CD8⁺DEC205⁺ DCs or CD8⁻33D1⁺ DCs.

  • They then monitored:

    • T cell activation using transgenic T cells (OT-I for MHC I; OT-II for MHC II)

    • MHC-peptide complex formation in the DCs

    • Gene and protein expression of antigen-processing machinery

Targeting Antibodies:

  • αDEC205-OVA → targets CD8⁺ DCs

  • 33D1-OVA → targets CD8⁻ DCs

In vitro and in vivo readouts included:

  • T cell proliferation (measured by CFSE dilution or thymidine incorporation)

  • Detection of MHC-peptide complexes on DC surfaces

  • Transgenic mice with altered receptor expression

Main Findings

1. Different Presentation Profiles for Different DC Subsets

  • CD8⁺DEC205⁺ DCs excel at cross-presentation (activating CD8⁺ T cells via MHC I).

  • CD8⁻33D1⁺ DCs are superior in MHC II-mediated antigen presentation (activating CD4⁺ T cells).

Figure 1F: CD8⁺ DCs activate OT-I (MHC I-specific) cells; CD8⁻ DCs activate OT-II (MHC II-specific) cells.

2. Antigen Uptake and Processing Differ

  • Antigen uptake by DEC205 is faster and more robust than 33D1 (Fig. 1H), but despite this:

    • MHC II peptide complexes accumulate more and persist longer on CD8⁻ DCs (Fig. 3A, 3B).

  • CD8⁺ DCs present MHC II peptides only briefly.

Interpretation: CD8⁻ DCs are better equipped to process and retain antigens for MHC II presentation.

3. T Cell Tolerance vs. Activation Depends on DC Maturation

  • Antigen presentation by unstimulated DCs led to T cell deletion or unresponsiveness (tolerance).

  • Co-stimulation via CD40 (DC activation) rescued the T cells and led to functional immune responses (Fig. 2F, 2G).

Critical Insight: Without maturation signals, antigen presentation can induce tolerance, not immunity.

4. Gene Expression Confirms Functional Specialization

  • CD8⁺ DCs express more MHCI pathway genes: TAP1/2, calreticulin, ERAAP, tapasin, etc.

  • CD8⁻ DCs express more MHCII pathway genes: cathepsins, AEP (legumain), GILT, H2-M (Fig. 4A–E).

These expression profiles match their functional antigen processing differences.

Critical Evaluation

Strengths:

  • In vivo targeting strategy is elegant and specific—mimics physiological conditions better than in vitro studies.

  • Clear T cell readouts (OT-I and OT-II systems) allow for precise functional dissection.

  • Gene/protein data directly support the functional differences observed.

  • The study is relevant for vaccine design and tolerance-inducing therapies.

Limitations and Considerations:

  • Artificial antibody-antigen fusion approach might not fully reflect natural antigen acquisition.

  • Antigen uptake speed differences could partially affect results (though they controlled for this using peptide-loaded DCs).

  • The transgenic mouse models used (e.g., CD11c-hDEC205) introduce overexpression artifacts.

  • Functional outcomes (e.g., cytokines, effector function) beyond T cell proliferation weren’t deeply explored.

  • The translation to human DC subsets is not discussed, though it would be highly relevant.

Key Takeaways for Your PhD Colloquium Presentation:

  • Dendritic cell subsets specialize in different antigen presentation pathways:

    • CD8⁺ DCs → cross-presentation (MHC I) → CD8⁺ T cells

    • CD8⁻ DCs → MHC II presentation → CD4⁺ T cells

  • Antigen targeting and DC maturation status dictate immune response outcome:

    • Without activation → tolerance

    • With CD40 stimulation → immunity

  • Molecular machinery in each DC subset supports its functional specialization.

Figure 1: Identifying DC Subsets and Their Antigen Presentation Capabilities

Panel A–C: Identifying DC Subsets in Mouse Spleen

  • What’s shown: Immunofluorescence and flow cytometry of splenic DCs.

    • CD8⁺DEC205⁺ DCs (red) localize in the T cell zone.

    • CD8⁻33D1⁺ DCs (green) are in the red pulp and marginal zone.

  • Why it matters: These subsets reside in distinct niches, suggesting specialized roles.

Panel D–E: Gene Expression of Lectins

  • What’s shown: mRNA expression of various lectins (antigen uptake receptors).

    • DEC205 is high in CD8⁺ DCs.

    • DCIR2 (recognized by 33D1 antibody) is high in CD8⁻ DCs.

  • Interpretation: Confirms distinct gene expression and uptake receptors in the two subsets.

Panel F: In Vitro Antigen Presentation Assay

  • What’s shown: DCs were targeted in vivo with OVA (ovalbumin) using antibodies and then tested in vitro for their ability to activate T cells:

    • CD8⁺ DCs (DEC205): Stimulate OT-I (MHC I-restricted) CD8⁺ T cells.

    • CD8⁻ DCs (33D1): Stimulate OT-II (MHC II-restricted) CD4⁺ T cells.

  • Conclusion: Confirms functional specialization:

    • CD8⁺ → MHC I → CD8⁺ T cells

    • CD8⁻ → MHC II → CD4⁺ T cells

Panel G–H: Antigen Uptake and Internalization

  • G: Only the targeted DC subset expresses the respective receptor (DEC205 or 33D1).

  • H: DEC205-mediated uptake is faster and more efficient than 33D1.

  • Critical note: Despite more uptake by DEC205, 33D1 still leads to better MHC II presentation—suggests that antigen processing (not just uptake) is the key differentiator.

Figure 2: T Cell Responses In Vivo and Tolerance

Panel A: In Vivo T Cell Proliferation (CFSE dilution)

  • OT-I and OT-II cells were injected after DCs were targeted with antigen:

    • DEC205-OVA → strong OT-I (CD8⁺) proliferation

    • 33D1-OVA → strong OT-II (CD4⁺) proliferation

  • Result: Confirms antigen presentation bias.

Panel B: Flow Cytometry of T Cells After Stimulation

  • Fewer OT-I cells are seen after 33D1-OVA injection, and vice versa.

  • Supports: Only matching DC subset effectively activates the appropriate T cells.

Panel C: Long-Term Antigen Presentation

  • Antigen presentation by DCs lasts several days:

    • OT-I still proliferates 10 days after DEC205-OVA.

    • OT-II still responds 5 days after 33D1-OVA.

Panel D–E: Induction of Tolerance

  • Without DC maturation, T cells are deleted or become nonresponsive.

  • Even though antigen is presented, the immune system tolerates it instead of attacking.

Panel F–G: Rescue of Immunity via CD40 Co-stimulation

  • When CD40 (a DC-activating stimulus) is co-administered:

    • T cells proliferate and persist.

    • They respond strongly upon re-exposure to the antigen.

  • Conclusion: DCs in steady state → tolerance.
    Activated DCs (via CD40) → immunity.

Figure 3: MHC II-Peptide Complex Formation

Panels A–B: HEL-MHCII Peptide Detection Over Time

  • Mice were injected with HEL antigen linked to DEC205 or 33D1.

    • CD8⁻ DCs (33D1): Show strong and sustained MHC II–peptide (MHCII-p) complexes.

    • CD8⁺ DCs (DEC205): Only weak and transient MHCII-p signals.

  • Interpretation: CD8⁻ DCs are more efficient at processing and presenting antigen on MHC II.

    Panel C: Transgenic Mice with Human DEC205

  • Both DC subsets express human DEC205 equally, yet:

    • Only CD8⁻ DCs show efficient MHCII-p presentation.

  • Conclusion: It’s not the receptor type (DEC205 vs. 33D1) but cell-intrinsic features of the DC subset that matter.

Figure 4: Gene and Protein Expression of Antigen Processing Machinery

Panels A–B: Gene Expression (Microarray)

  • CD8⁻ DCs (33D1): High expression of MHC II-processing genes:

    • Cathepsins (C, H, Z), GILT, AEP, H2-M

  • CD8⁺ DCs (DEC205): High expression of MHC I-processing genes:

    • TAP1, TAP2, calreticulin, calnexin, ERAAP, tapasin

Panel C: Intracellular FACS for MHC II Components

  • Confirms higher expression of H2-M (MHC II chaperone) in CD8⁻ DCs.

Panels D–E: Western Blots

  • D: MHC II proteins (Cathepsins, GILT, AEP) enriched in CD8⁻ DCs.

  • E: MHC I proteins (TAP1, tapasin, calnexin, etc.) enriched in CD8⁺ DCs.

Panel F: Loading Controls

  • LAMP1 and β-actin used as internal controls for equal protein loading.

Overall Interpretation of All Figures

  • Functional data (T cell assays) match molecular expression profiles.

  • CD8⁻ DCs are intrinsically better at MHC II presentation due to:

    • Higher levels of MHC II machinery.

    • More sustained surface expression of peptide–MHC II complexes.

  • CD8⁺ DCs excel at MHC I presentation and cross-presentation.

  • T cell outcome (tolerance vs. activation) is not just about antigen, but also about DC activation status.